CanSino Biologics and Precision NanoSystems Announce Collaboration

The partners will work on an mRNA nanoparticle vaccine for COVID-19, with Precision NanoSystems designing the vaccine and CanSino undergoing preclinical and clinical development, regulatory activities and commercialization.

Atea has raised USD 215 Million to support mid-phase COVID-19 antiviral trials.

The series D establish Atea to run a phase 2 trial of its oral purine nucleotide prodrug in people, who have been hospitalized with moderate cases of COVID-19.

Applied Molecular Transport targets for USD 100 Million IPO

Applied Molecular Transport is aiming for a USD 100 million IPO to bring its lead program that is an oral IL-10 agonist, into phase 2 studies.

Cell therapy repairs multiple sclerosis in mice.

A team of researchers at the URMC is developing a method for regenerating myelin with progenitor glial cells. When they transplanted the cells into mouse models of MS, the cells transformed into new oligodendrocytes and restored myelin.

For more information visit:

https://www.delveinsight.com/blog/recent-pharma-happenings-for-cansino-atea-precision-nanosystems/